Researchers from the uOttawa Faculty of Medicine and affiliated institutes have attracted more than $22 million in the latest funding allocations from the Canadian Institutes of Health Research (CIHR).
The CIHR funding supports researchers in all areas of health and aims to capture ideas with the greatest potential to advance health-related fundamental or applied knowledge, health research, health care, health systems, and/or health outcomes. Thank you to CIHR for their continued support for Faculty of Medicine researchers, who continue to make the Faculty of Medicine a leading research-intensive institution.
Well done to all of the research groups on behalf of the entire Faculty of Medicine community!
- Côté, Marceline - Characterization of filovirus host factors and small-molecule inhibitors of infection
- Couture, Jean-François - Investigating the role of a lysine methyltransferase in breast cancer progression
- Ferguson, Stephen S - Modulation of Glutamatergic Signaling in Huntington's Disease Progression
- Gadde, Suresh - miRNA-based targeted nanotherapies for atherosclerosis
- Jahani-Asl, Arezu - Transcriptional Regulation of Impaired Neurogenesis in Developmental Disorders of Cognition and Intellectual Disability
- Lohnes, David L - Cdx and Intestinal Homeostasis
- Sad, Subash - Role of Type I interferon signaling in the murine typhoid model
- Saghatelyan, Armen - Integration and decoding of micro-environmental signals in neural stem cells
- Saghatelyan, Armen - The involvement of different brain regions in odor processing
- Sun, Jim - Host-directed drug development for tuberculosis
- Burger, Dylan E - The maternal endothelium in gestational diabetes mellitus
- El-Chaar, Darine - Infant and child health outcomes following SARS-CoV-2 infection in pregnancy
- Hatcher, Simon - Development of a suicide prevention strategy for Public Safety Personnel
- Kothary, Rashmi K - Extra-neuronal contribution to spinal muscular atrophy disease pathogenesis
- Lavallée, Luke T - PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
- Murthy, Sanjay K - A Randomized Controlled Non-Inferiority Trial to Assess the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Adult Inflammatory Bowel Disease
- Parks, Robin J - Epigenetic Regulation of the Adenovirus Genome
- Seely, Andrew J - Evaluating and Improving a National Learning Network
- Shea, Beverley J - AMSTAR-DTA: A Measurement Tool to Assess Systematic Reviews of Diagnostic Test Accuracy Studies
- Siegal, Deborah M - Reducing Gastrointestinal Bleeding with Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism (RADIANT) Pilot Randomized Trial
- Stewart, Duncan J - Imbalance Between Vascular Injury and Repair in PAH
- Thebaud, Bernard - Therapeutic potential of stem cells in lung injury
- Vanderhyden, Barbara C - Increasing anti-tumoral responses to ovarian cancer using engineered viruses
- Isenberg, Sarina R - Building system capacity for home visits for patients near the end of life: A mixed methods study
- Alain, Tommy - Viralyzing transgenes to improve oncolytic immunotherapy
- Berman, Jason N - Identifying novel strategies for leukemia prevention using zebrafish models of dnajc21-mutant Shwachman Diamond syndrome
- Katz, Sherri L - Early-life MRI biomarkers of longer-term respiratory morbidity in infants born extremely preterm (EMBLEM)
- Jaworska, Natalia - Characterizing the Neural Profiles of Bipolar Disorder with and without Auditory Hallucinations
- Chih, Sharon S - Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation: MARINER Trial
- Mulvihill, Erin E - Targeting Macrophage Differentiation and Function in Atherosclerosis
- Ruel, Marc - One-month DAPT In CABG PatieNts: the ODIN trial
Consider supporting the University of Ottawa
The Faculty Of Medicine's Greatest Needs fund provides the most flexible support for the evolving, highest needs and priorities identified in the strategic plan – Leading Innovation for a Healthier World.